204 related articles for article (PubMed ID: 21623643)
1. Ambrisentan.
Frampton JE
Am J Cardiovasc Drugs; 2011 Aug; 11(4):215-26. PubMed ID: 21623643
[TBL] [Abstract][Full Text] [Related]
2. Ambrisentan.
Croxtall JD; Keam SJ
Drugs; 2008; 68(15):2195-204. PubMed ID: 18840007
[TBL] [Abstract][Full Text] [Related]
3. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
[TBL] [Abstract][Full Text] [Related]
4. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of ambrisentan.
Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
[TBL] [Abstract][Full Text] [Related]
6. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Badesch DB; Feldman J; Keogh A; Mathier MA; Oudiz RJ; Shapiro S; Farber HW; McGoon M; Frost A; Allard M; Despain D; Dufton C; Rubin LJ;
Cardiovasc Ther; 2012 Apr; 30(2):93-9. PubMed ID: 21884013
[TBL] [Abstract][Full Text] [Related]
7. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
[TBL] [Abstract][Full Text] [Related]
8. An update on the use of ambrisentan in pulmonary arterial hypertension.
D'Alto M
Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
[TBL] [Abstract][Full Text] [Related]
10. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
11. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
[TBL] [Abstract][Full Text] [Related]
12. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
Peacock AJ; Zamboni W; Vizza CD
Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
[TBL] [Abstract][Full Text] [Related]
13. A review of pulmonary arterial hypertension: role of ambrisentan.
Barst RJ
Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
16. Ambrisentan for the management of pulmonary arterial hypertension.
Cheng JW
Clin Ther; 2008 May; 30(5):825-33. PubMed ID: 18555930
[TBL] [Abstract][Full Text] [Related]
17. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan and its role in the management of pulmonary arterial hypertension.
Macintyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
